Ibn Al Haytham Hospital Company PSC

The company's capital structure shows a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. However, the current ratio of 0.61 suggests potential liquidity constraints, as current assets fall short of current liabilities. The negative free cash flow of -840,100 JOD and a capital expenditure of -2,206,470 JOD indicate ongoing investment in infrastructure, which may be necessary for long-term growth but could strain short-term liquidity. Profitability metrics show a return on equity (ROE) of 2.38% and a return on assets (ROA) of 1.06%, both below the typical thresholds for high-performing healthcare facilities. These figures suggest that the company is generating modest returns relative to its equity and asset base. The operating margin, calculated as operating income of 379,380 JOD on revenue of 12,141,460 JOD, is approximately 3.12%, which is in line with the industry's lower end. The company's revenue is primarily concentrated in Jordan, with no disclosed international operations. The hospital's 200-bed capacity and 38 clinics suggest a focus on domestic healthcare delivery, but the lack of geographic diversification could expose the company to regional economic or political risks. The company's growth trajectory is not clearly defined in the provided data, as there are no forward-looking revenue projections or historical growth rates. The capital expenditure of -2,206,470 JOD indicates ongoing investment, but without a clear link to future revenue growth, it is difficult to assess the long-term impact of these investments. The risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to secure additional financing in the near term. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near future. Recent events and filings are not detailed in the provided data, so it is not possible to assess the company's recent performance or strategic direction based on disclosed events or transcripts.